References

  1. RICHARDSON P., MCKENNA W., BRISTOW M., MAISCH B., MAUTNER B., O´CONNELL J., OLSEN E., THIENE G., GOODWIN J., GYARFAS I., MARTIN I., NORDER P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation, 93(5), 841–842.
  2. ELLIOTT P., ANDERSSON B., ARBUSTINI E., BILINSKA Z., CECCHI F., CHARRON P., DUBOURG O., KÜHL U., MAICH B., MCKENNA W.J., MOSERRAT L., PANKUWEIT S., RAPEZZI C., SEFEROVIC P., TAVAZZI L., KEREN A. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. European Heart Journal [online]. 2008, -(29), 270–276 [cit. 2016-08-10].
  3. T., ARETZ a et al. Myocarditis. A histopathologic definition and classification. The American Journal of Cardiovascular Pathology [online]. 1986, 1(1), 3-14 [cit. 2017-02-06].
  4. AL-AQEEDI R.F., Chapter 2: Clinical Presentation. In: WILSON J. Clinical Handbook of Myocarditis. New Jersey: Foster Academics, 2015. pp. 33–69. ISBN: 978-1-63242-083-1.
  5. MAISCH B., BÜLTMAN B., FACTOR S., GRÖNE H.-J. et al. World Heart Federation Consensus Conferences Definition of Inflammatory Cardiomyopathy (Myocarditis): Report from two Expert Committees on Histology and Viral Cardiomyopathy. Herz [online]. 2000, 25 (3), 200-209 [cit. 2016-08-26].
  6. KARJALAINEN, J. a J. HEIKKILÄ. Incidence of three presentations of acute myocarditis in young men in military service: A 20-year experience. European Heart Journal. 1999, -(20), 1120-1125.
  7. GRAVANIS, M.B. a N.H. STERNBY. Incidence of myocarditis. A 10-year autopsy study from Malmö, Sweden. Arch Pathol Lab Med [online]. 1991, 115(4), 390-392 [cit. 2016-09-02].
  8. ZEMÁNEK D. Kapitola 15: Zánětlivé onemocnění myokardu. In: VESELKA, J. a V.ROHN. Kardiovaskulární medicína [online]. 1. vydání. Brno: Fasta Medica, 2015. ISBN 978-80-88056-00-3.
  9. BASSO, C. a F. CALABRESE. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. Cardiovascular Research [online]. 2001, -(50), 290-300 [cit. 2016-09-02].
  10. TOWBIN, J. A., A. P. LOWE a et al. Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children. JAMA. 2006, -(296), 1867-1876.
  11. O´CONNELL, J. B., A. HERSKOWITZ a et al. A Clinical Trial of Immunosuppressive Therapy for Myocarditis. New England Journal of Medicine. 1995, -(333), 269-275.
  12. CANTER, CH. E., M. W. CUNNINGHAMB a L. T. COOPER. Recent clinical and translational research on pediatric myocarditis. Prog Pediatr Cardiol. 2011, 32(1), 15–18.
  13. UHL, T. L. Viral Myocarditis in Children. PediatricCare. 2008, 28(1), 42–63. (podle Friedman RA. Myocarditis. In: Garson A, Bricher JT, McNamara DG, eds. The Science and Practice of Pediatric Cardiology. Philadelphia, PA: Lea & Febiger; 1990: 1577-1589. + Park MK, Troxler RG. Pediatric Cardiology for Practitioners. 4th ed. St Louis, MO: Mosby; 2002:289-290.)
  14. FABRE, A. a M. N. SHEPPARD. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006, -(92), 316-320.
  15. FAQ on Sudden Death and Myocarditis. Myocarditis Foundation [online]. -: -, 2012 [cit. 2016-10-18]. (Podle Feldman AM, McNamara D. Myocarditis. The New England journal of medicine 2000;343:1388-98.)
  16. KUBÁNEK M., Kapitola 8.2.: Myokarditidy. In: KAUTZNER J., MELENOVSKÝ V., et al. Srdeční selhání – aktuality pro klinickou praxi. Praha: Mladá fronta a.s., 2015. pp. 147–157. ISBN: 978-80-204-3573-6.
  17. TAVLI V., GUVEN B., Chapter 1: Myocarditis in Childhood: An Update on Etiology, Diagnosis and Management. In: WILSON J. Clinical Handbook of Myocarditis. New Jersey: Foster Academics, 2015. pp. 3–32. ISBN: 978-1-63242-083-1.
  18. OMAR H.R., ABDELMALAK H., HELAL E., MIKHAEIL Y., FATHY A. Chapter 5: Perimyocarditis. In: WILSON J. Clinical Handbook of Myocarditis. New Jersey: Foster Academics, 2015. pp. 105–118. ISBN: 978-1-63242-083-1.
  19. MÜLLEROVÁ J., NOVÁK M. a VÍTOVEC J. Myokarditidy. Kardiologická revue. 2003, -(2), 56-59.
  20. , UKIMURA a et al. A National Survey on Myocarditis Associated With the 2009 Influenza A (H1N1) Pandemic in Japan. Circulation Journal. 2010, 74(-), 2193-2199.
  21. ELAMM, Chantal, DeLisa FAIRWEATHER a Leslie T. COOPER. Pathogenesis and diagnosis of myocarditis. Heart. 2012, – (-), -.
  22. SAGAR, Sandeep, Peter P. LIU a Leslie T. COOPER, JR. Myocarditis. Lancet. 2012,379(-), 738–747.
  23. SCHULTHEISS, Heinz-Peter, Uwe KÜHL a Leslie T. COOPER, JR. The management of myocarditis. European Heart Journal. 2011, 32(-), 2616–2625.
  24. CAFORIO, A.L.P, PANKUWEIT S., ARBUSTINI E., et al. Current state knowledge on aetiology, diagnosis, management, and Therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal. 2013, 34(-), 2636–2648.
  25. ABDULLAH, M.A.A., L.P. STRAATMAN a et al. Eosinophilic myocarditis: Case series and review of literature. Canadian Journal of Cardiology. 2006, 22(14), 1233–1237.
  26. COOPER L. T., JR., KNOWLTON K. U. Chapter 67: Myocarditis. In.: D.P., ZIPES, MANN D.L., LIBBY P., BONOW R.O. a BRAUNWALD E. (eds.). Braunwald´s Heart Disease: A Textbook of Cardiovascular medic Tenth edition. Philadelphia: Elsevier Saunders, 2015. pp. 1589–1602. ISBN 978-1-4557-5133-4.
  27. GRÜN, S., SCHUMANN J. a et al. Long-Term Follow-Up of Biopsy-Proven Viral Myocarditis: Predictors of Mortality and Incomplete Recovery. JACC. 2012, 59(18), 1604-1615.
  28. KREJČÍ, J., P. HUDE a et al. Endomyokardiální biopsie u recentní dilatační kardiomyopatie – zhodnocení vstupních charakteristik prvních padesáti nemocných. Cor et Vasa. 2011, -(53), 623-629.
  29. KUCHYNKA, P. Nové diagnostické a terapeutické aspekty zánětlivé kardiomyopatie. Praha, 2011. Disertační práce. 1. LF UK.
  30. COOPER JR., L.T., A. KEREN a et al. The Global Burden of Myocarditis: Part 1: A Systematic Literature Review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. Global Heart. 2014, 9(1), 121-129.
  31. HAAS, S. J., R. HILL a et al. Clozapine-Associated Myocarditis: Review of 116 Cases of Suspected Myocarditis Associated with the Use of Clozapine in Australia During 1993–2003. Drug Safety. 2007, 30(1), 47-57.
  32. ANDERSON, D. W., R. VIRMANI a et al. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. Jornal of American College of Cardiology. 1988, 11(4), 792-799.
  33. CAMBREA S. C. Chapter 8: Myocarditis in HIV Positive Patients. In: WILSON J. Clinical Handbook of Myocarditis. New Jersey: Foster Academics, 2015. pp. 165-182. ISBN: 978-1-63242-083-1.
  34. FISHER S. D., LIPSHULTZ S. E. Cardiovascular Abnormalities in HIV-Infected Individuals.: D.P., ZIPES, MANN D.L., LIBBY P., BONOW R.O. a BRAUNWALD E. (eds.). Braunwald´s Heart Disease: A Textbook of Cardiovascular medicine. Tenth edition. Philadelphia: Elsevier Saunders, 2015. pp. 1624–1635. ISBN 978-1-4557-5133-4.
  35. KUETHE, F., J. LINDNER a et al. Prevalence of Parvovirus B19 and Human Bocavirus DNA in the Heart of Patients with no Evidence of Dilated Cardiomyopathy or Myocarditis. Clinical Infectious Diseases. 2009, -(49), 1660-1666.
  36. POLLER, W., H. FECHNER a et al. The molecular basis of cardiotropic viral infections. European Heart Journal Supplements [online]. 2002, -(4), 118–130 [cit. 2016-09-14].
  37. LAURENT A. Chapter 3: Viral Myocarditis: Physiopathology and Diagnosis. In: WILSON J. Clinical Handbook of Myocarditis. New Jersey: Foster Academics, 2015. pp. 69-86. ISBN: 978-1-63242-083-1.
  38. ŠTEINER, I. Kardiopatologie: pro patology i kardiology. Praha: Galén, 2010. ISBN 978-80-7262-672-4.
  39. CAFORIO, A.L.P, PANKUWEIT S., ARBUSTINI E., et al. Current state knowledge on aetiology, diagnosis, management, and Therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal. 2013, 34(-), 2636–2648 podle referencí 72, 77, 57, 64, 9, 50, 35, 36, 118, 52, 48, 55, 61–63, 66, 72, 74–76, 78, 84, 109, 88, 90, 92, 93, 98, 53, 62, 69, 89, 47, 48, 54, 58, 59, 70, 74–75, 88, 94, 98, 67 uvedených v tomto článku.
  40. HASENFUSS, G., MANN, D. L. Chapter 22: Pathophysiology of Heart Failure. In.: D. P., ZIPES, MANN D.L., LIBBY P., BONOW R.O. a BRAUNWALD E. (eds.). Braunwald´s Heart Disease: A Textbook of Cardiovascular medicine. Tenth edition. Philadelphia: Elsevier Saunders, 2015. pp. 454–472. ISBN 978-1-4557-5133-4.
  41. ELAMM, Chantal, DeLisa FAIRWEATHER a Leslie T. COOPER. Pathogenesis and diagnosis of myocarditis. Heart. 2012, -(-), – podle referencí 11, 20, 30, 32 uvedených v tomto článku.
  42. L., BAUGHMAN. Diagnostika myokarditidy: Dallaským kritériím odzvonilo. Circulation-CZ. 2006, 5(1), 7-9.
  43. M, HOLICKÁ a ŠPINAR J. Myokarditidy. ACTA MEDICINAE. 2013, 2013(7), 68-74.
  44. , BAANDRUP. Eosinophilic myocarditis. Herz. 2012, 2012(37), 849-853.
  45. E., ECKART a et al. Incidence and Follow-Up of Inflammatory Cardiac Complications After Smallpox Vaccination. Journal of the American College of Cardiology. 2004, 44(1), 201-205.
  46. , KUCHYNKA a et al. Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis. BioMed Research International [online]. 2016, 2016(-), 6 stran [cit. 2017-02-05].
  47. E., PETERSEN a et al. Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance. Heart [online]. 2005, 91(1), e9 [cit. 2017-02-07].
  48. J., DAVIES a et al. Idiopathic giant cell myocarditis-a distinctive clinico-pathological entity. British Heart Journal [online]. 1975, 1975(37), 192-195 [cit. 2017-02-05].
  49. , OKURA a et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. Journal of the American College of Cardiology [online]. 2003, 41(2), 322 [cit. 2017-02-05].
  50. , KUBÁNEK a VOSKA L. Obrovskobuněčná myokarditida a sarkoidóza srdce – update 2015. Kardiologická revue – Interní medicína. 17(4), 295-299.
  51. T., JR., COOPER. Chapter 17: Idiopathic Giant Cell Myocarditis. In: L.T., JR., COOPER, ed. Myocarditis: From Bench to Bedside. USA: Humana Press, 2003. pp. 405-420. ISBN 1-58829-112-X.
  52. Giant Cell Myocarditis. National Organization for Rare Disorders [online]. USA: -, 2006 [cit. 2017-02-07].
  53. K., BENNETT a et al. Evaluation of the Role of Endomyocardial Biopsy in 851 Patients With Unexplained Heart Failure From 2000–2009. Circulation: Heart Failure [online]. 2013, 2013(6), 676-684 [cit. 2017-02-05].
  54. D., BINHUTI a et al. Cardiac Transplantation for Pediatric Giant Cell Myocarditis. Journal of Heart Lung Transplant. 2006, 2006(25), 474-478.
  55. T., JR., COOPER a et al. IDIOPATHIC GIANT-CELL MYOCARDITIS — NATURAL HISTORY AND TREATMENT. The New England Journal of Medicine. 1997, 1997(336), 1860-1866.
  56. , KANDOLIN a et al. Diagnosis, Treatment, and Outcome of Giant-Cell Myocarditis in the Era of Combined Immunosuppression. Circulation: Heart Failure [online]. 2013, 2013(6), 15-22 [cit. 2017-02-05].
  57. A., CHAUDHRY a et al. Modern day management of giant cell myocarditis. International Journal of Cardiology. 2015, 2015(178), 82-84.
  58. T., JR., COOPER. Chapter 18: Cardiac Sarcoidosis. In: L.T., JR., COOPER, ed. Myocarditis: From Bench to Bedside. USA: Humana Press, 2003. pp. 421-436. ISBN 1-58829-112-X.
  59. , MORIMOTO a et al. Epidemiology of sarcoidosis in Japan. European Respiratory Journal [online]. 2008, 31(-), 372-379 [cit. 2017-02-07].
  60. , KANDOLIN. Cardiac Sarcoidosis: Epidemiology, Characteristics and Outcome over 25 Years in a Nationwide Study. Circulation [online]. 2014, 2014(-), 1-35 [cit. 2017-02-05].
  61. B., NERY a et al. Isolated Cardiac Sarcoidosis: Establishing the Diagnosis With Electroanatomic Mapping-Guided Endomyocardial Biopsy. Canadian Journal of Cardiology. 2013, 2013(29), 1015.e1 – 1015.e3.
  62. H., BIRNIE a et al. HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm. 2014, 11(7), 1304–1323.
  63. , SHIRANI a et al. CARDIOVASCULAR IMAGING IN CLINICAL AND EXPERIMENTAL ACUTE INFECTIOUS MYOCARDITIS. Frontiers in Bioscience. 2003, 8(-), e323 – e336.
  64. Cardiac Involvement in the Acquired Immunodeficiency Syndrome: A Multicenter Clinical-Pathological Study. Mary Ann Liebert, Inc. publishers [online]. USA: Mary Ann Liebert, Inc. publishers, 2009 [cit. 2017-02-05].
  65. F., CURRIE a et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart [online]. 1998, 79(-), 599-604 [cit. 2017-02-05].
  66. H., LUMSDEN a et al. The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds. BioMed Research International [online]. 2016, 2016(-), 9 stránek [cit. 2017-02-05].
  67. REMICK a et al. Heart Failure in Patients With Human Immunodeficiency Virus Infection. Circulation [online]. 2014, 129(17), 1781-1789 [cit. 2017-02-05].
  68. OLSON L. J. Chapter 22: Myocarditis Associated With Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. In: L.T., JR., COOPER, ed. Myocarditis: From Bench to Bedside. USA: Humana Press, 2003. pp. 545–558. ISBN 1-58829-112-X.
  69. S., BLOOMFIELD a et al. Human Immunodeficiency Virus and Heart Failure in Low-and Middle-Income Countries. JACC: Heart Failure. 2015, 3(8), 579–590.
  70. , KISELNIK a et al. Acute Myocarditis and Myopathy as Presenting Manifestations of Human Immunodeficiency Virus Infection. IMAJ [online]. 2015, 17(-), 524-525 [cit. 2017-02-05].
  71. E., LIPSHULTZ a et al. Immunoglobulins and Left Ventricular Structure and Function in Pediatric HIV Infection. Circulation [online]. 1995, 92(8), 2220-2225 [cit. 2017-02-05].
  72. M., FELKER a et al. Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy. The New England Journal of Medicine [online]. 2000, 342(-), 1077-1084 [cit. 2017-02-05].
  73. F., CURRIE a et al. Heart muscle disease related to HIV infection: prognostic implications. BMJ [online]. 1994, 309(1605), – [cit. 2017-02-05].
  74. D., FISHER a et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: The Prospective P2C2 HIV Multicenter Study. America Heart Journal [online]. 2005, 150(3), 439–447 [cit. 2017-02-05].
  75. MASON J. C. Chapter 84: Rheumatic Diseases and the Cardiovascular System. In.: D.P., ZIPES, MANN D.L., LIBBY P., BONOW R.O. a BRAUNWALD E. (eds.). Braunwald´s Heart Disease: A Textbook of Cardiovascular medicine. Tenth edition. Philadelphia: Elsevier Saunders, 2015. pp. 1843–1862. ISBN 978-1-4557-5133-4.
  76. Srdce a systémová onemocnění. ECardio.cz [online]. -: -, – [cit. 2017-02-05].
  77. , ZHANG a et al. Lupus Myocarditis: A Case–Control Study from China. Chin Med J (Engl) [online]. 2015, 128(19), 2588-2594 [cit. 2017-02-05].
  78. Recurrent lymphocytic myocarditis in a young male with ulcerative colitis. Varnavas, Varnavas C et al. “Recurrent Lymphocytic Myocarditis in a Young Male with Ulcerative Colitis.” European Journal of Medical Research 19.1 (2014): 11. PMC. Web. 5 Feb. 2017. [online]. 2014, 19(1), – [cit. 2017-02-05].
  79. H., KATSANOS a et al. The heart in inflammatory bowel disease. ANNALS OF GASTROENTEROLOGY. 2002, 15(2), 124-133.
  80. , ROCZEK a et al. Myopericarditis in a patient with ulcerative colitis treated with mesalamine—Case report and review of the literature. Journal of Cardiology Cases [online]. 2014, 10(-), 104-107 [cit. 2017-02-05].
  81. , FRUSTACI a et al. Celiac Disease Associated With Autoimmune Myocarditis. Circulation [online]. 2002, 105(22), 2611-2618 [cit. 2017-02-05].
  82. , ZAHMATKESHAN a et al. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. Iran J Pediatr [online]. 2014, 24(5), 587-592 [cit. 2017-02-05].
  83. , ROMAGNOLI a et al. Association between celiac disease and idiopathic dilated cardiomyopathy: a case report. Internal and Emergency Medicine [online]. 2011, 6(2), 125-128 [cit. 2017-02-05].
  84. , BOSKOVIC a et al. Cardiomyopathy Associated with Celiac Disease in Childhood. Case Rep Gastrointest Med [online]. 2012, 2012(-), – [cit. 2017-02-05].
  85. , DENNERT a et al. Acute viral myocarditis. European Heart Journal. 2008, 29(-), 2073-2082.
  86. E., AMM a COOPER L.T., JR. Management of myocarditis. Heart Metab. 2014, 62(2014), 8-12.
  87. E., MCCARTHY a et al. Long-Term Outcome of Fulminant Myocarditis as Compared with Acute (Nonfulminant) Myocarditis. The New England Journal of Medicine [online]. 2000, 342(-), 690-695 [cit. 2017-02-07].
  88. HROBOŇOVÁ V. Kapitola 58: Revmatická horečka In V., CHALOUPECKÝ a et al. Dětská kardiologie. Praha: Galén, 2006. pp. 335-339 ISBN 80-7262-406-5.
  89. GLOBAL BURDEN OF DISEASE STUDY 2015. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. 2016, 388(-), 1546-1602, konkrétně 1563.
  90. , KAMBLOCK a et al. Does rheumatic myocarditis really exists? Systematic study with echocardiography and cardiac troponin I blood levels. European Heart Journal. 2003, 24(-), 855-862.
  91. What is Chagas disease? WHO [online]. -: -, 2016 [cit. 2017-02-09].
  92. , JR., RASSI a et al. Chagas disease. Lancet. 2010, 375(-), 1388-1402.
  93. H., MALIK a et al. The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. Clin. Cardiol. 2015, 38(9), 565-569.
  94. , BYSTRIANSKY. Kardiovaskulárne postihnutie pri Chagasovej chorobe. Očkování a cestovní medicína. 2015, 6(-), 35-38.
  95. -X., LESCURE a et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis. 2010, 10(-), 556-570.
  96. Onemocnění myokardu: Myokarditida, zánětlivá kardiomyopatie. ECardio.cz [online]. -: -, – [cit. 2017-01-30].
  97. KUCHYNKA P. Kapitola 8.1. Akutní myokarditida. In: MOŤOVSKÁ, Z. a et al. Novinky v akutní kardiologii. Praha: Mladá fronta, 2016. pp. 292–303. ISBN 978-80-204-3903-1.
  98. KINDERMANN, I. a et al. Update on Myocarditis. Journal of the American College of Cardiology. 2012, 59(9), 779-792.
  99. KUCHYNKA, P. a et al. Myokarditida a zánětlivá kardiomyopatie. Kapitoly z kardiologie. 2013, 3(-), 87-91.
  100. KREJČÍ, J. Myokarditidy a zánětlivé kardiomyopatie. Kardiologická Revue Interní Medicína. 2015, 17(4), 288-294.
  101. TOMEK, V. Kapitola 56: Myokarditidy. In: CHALOUPECKÝ, V. a et al. Dětská kardiologie. Praha: Galén, 2006. pp. 327-329. ISBN 80-7262-406-5.
  102. STARÁ, V. Nestrukturální srdeční onemocnění u dětí. Vox Pediatriae. 2006, 6(4), 26-32.
  103. UKENA, CH. a et al. Prognostic electrocardiographic par ametersin patients with suspected myocarditis. European Journal of Heart Failure [online]. 2011, 13(-), 398-405 [cit. 2017-02-27].
  104. FERRI, F. F. a et al. Ferri’s Clinical Advisor 2015: 5 Books in 1 [online]. -. USA: Elsevier, 2015 [cit. 2017-02-27]. pp. 807-809. ISBN 978-0-323-08375-1.
  105. BACKER, D.D., ed. et al. Hemodynamic Monitoring Using Echocardiography in the Critically Ill [online]. -. Berlin: Springer, 2011 [cit. 2017-02-27]. pp. 124. ISBN 978-3-540-87954-1.
  106. PLEVA, M. Kapitola 6: Akutní myokarditida. In: PLEVA, M. a P. OUŘEDNÍČEK. MRI srdce. Praha: Grada Publishing, 2012. pp. 83-86. ISBN 978-80-247-3931-1.
  107. FRIEDRICH, M.G. a et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper. Journal of the American College of Cardiology. 2009, 53(17), 1475-1487.
  108. MAHDOUD, F. a et al. Virus serology in patients with suspected myocarditis: utility or futility? European Heart Journal. 2011, 32(-), 897-903.
  109. BRAUNWALD, E. Biomarkers in Heart Failure. The New England Journal of Medicine. 2008, 358(-), 2148-2159.
  110. TEELE, S.A. Management and Outcomes in Pediatric Patients Presenting with Acute Fulminant Myocarditis. The Journal of Pediatrics. 2011, 158(4), 638-643.
  111. LAUER, B. a et al. Cardiac Troponin T in Patients With Clinically Suspected Myocarditis. JACC. 1997, 30(5), 1354-1359.
  112. AL-BILTAGI, M. Circulating cardiac troponins levels and cardiac dysfunction in children with acute and fulminant viral myocarditis. Acta Pediatrica. 2010, 99(-), 1510-1516.
  113. JANUZZI, J.L., MANN, D.L. Chapter 23: Clinical Assessment of Heart Failure. In.: D.P., ZIPES, MANN D.L., LIBBY P., BONOW R.O. a BRAUNWALD E. (eds.). Braunwald´s Heart Disease: A Textbook of Cardiovascular medicine. Tenth edition. Philadelphia: Elsevier Saunders, 2015. pp. 473-483. ISBN 978-1-4557-5133-4.
  114. ZHANG, CH. a et al. [Prognostic value of brain natriuretic peptide in people with viral myocarditis].: Abstract. Chinese Journal of Experimental and Clinical Virology [online]. 2012, 26(2), 125-126 [cit. 2017-02-27].
  115. NEUMANN, D.A. a et al. Circulating Heart-Reactive Antibodies in Patients With Myocarditis or Cardiomyopathy. JACCC. 1990, 16(4), 839-846.
  116. , B. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin. exp. Immunol. 1982, 48(-), 533-545.
  117. JAHNS, R. a et al. Autoantibodies Activating Human β1-Adrenergic Receptors Are Associated With Reduced Cardiac Function in Chronic Heart Failure. Circulation [online]. 1999, 99(5), 649-654 [cit. 2017-02-27].
  118. LAUER, B. a et al. Antimyosin Autoantibodies Are Associated With Deterioration of Systolic and Diastolic Left Ventricular Function in Patients With Chronic Myocarditis. JACC. 2000, 35(1), 11-18.
  119. HIRVELÄ, J.-L. a et al. Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. European Journal of Clinical Investigation. 2009, 39(6), 457-462.
  120. CAFORIO, A.L.P. a et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008, 41(1), 35-45.
  121. CALABRESE, F. a et al. Yocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovascular Research [online]. 2003, 60(-), 11-25 [cit. 2017-02-27].
  122. HEYMANS, S. a et al. The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. JACC. 2016, 68(21), 2348-2364.
  123. COOPER, L.T., Jr. a et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. JACC. 2007, 50(19), 1914-1931.
  124. DECKERS, J.W. a et al. Complications of Transvenous Right Veatricular Endomyocardial Biopsy in Adult Patients With Cardiomyopathy: A Seven-Year Survey of 546 Consecutive Diagnostic Procedures in a Tertiary Referral Center. JACC [online]. 1992, 19(1), 43-47 [cit. 2017-02-27].
  125. FROM, A.M. a et al. Current Status of Endomyocardial Biopsy. Mayo Clin Proc. [online]. 2011, 86(11), 1095-1102 [cit. 2017-02-27].
  126. LEONE, O. a et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovascular Pathology. 2012, 21(-), 254-274.
  127. JCS Joint Working Group. Guidelines for Diagnosis and Treatment of Myocarditis (JCS 2009). Circulation Journal. 2011, 75(-), 734-743.
  128. MARON, B.J. a et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. JACC [online]. 2005, 45(8), 1340-1345 [cit. 2017-02-27].
  129. CABINIAN, A.E. a et al. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model: Abstract. J Lab Clin Med. [online]. 1990, 115(4), 454-462 [cit. 2017-02-27].
  130. Kapitola 13: Antihypertenziva – léčiva ovlivňující systém renin-angiotenzin-aldosteron. In: SLÍVA, J. a M. VOTAVA. Farmakologie. Praha: Triton, 2011. pp. 79-85. ISBN 978-80-7387-500-8.
  131. BAHK, T.J. a et al. Comparison of Angiotensin Converting Enzyme Inhibition and Angiotensin II Receptor Blockade for the Prevention of Experimental Autoimmune Myocarditis. Int J Cardiol. [online]. 2008, 125(1), 85-93 [cit. 2017-02-27].
  132. YUAN, Z. a et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. American Journal of Physiology [online]. 2004, 286(1), H83-H90 [cit. 2017-02-27].
  133. REZKALLA, S. a et al. Effect of Metoprolol in Acute Coxsackievirus B3 Murine Myocarditis. JACC [online]. 1988, 12(2), 412-414 [cit. 2017-02-27].
  134. Kapitola 12: Diuretika. In: SLÍVA, J. a M. VOTAVA. Farmakologie. Praha: Triton, 2011. pp. 127-130. ISBN 978-80-7387-500-8.
  135. VEERAVEEDU, P.T. a et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. European Journal of Pharmacology. 2008, 581(-), 121-131.
  136. JIE, X. a et al. Anti-inflammatory effects of eplerenone on viral myocarditis. European Journal of Heart Failure [online]. 2009, 11(-), 349-353 [cit. 2017-02-27].
  137. YUE-CHUN, L. a et al. The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy: Article 408. Frontiers in Pharmacology. 2016, 7(-), 1-10.
  138. MATSUMORI, A. a et al. High Doses of Digitalis Increase the Myocardial Production of Proinflammatory Cytokines and Worsen Myocardial Injury in Viral Myocarditis: A Possible Mechanism of Digitalis Toxicity. Jpn Circ J [online]. 1999, 63(-), 934-940 [cit. 2017-02-27].
  139. Kapitola 22.5.1. Myokarditidy. In: ASCHERMANN, M., ed. Kardiologie. Praha: Galén, 2004. pp. 840-845. ISBN 80-7262-290-0.
  140. PALEČEK, T. Inflammatory cardiomyopathy: Still many questions await answers. Cor et Vasa. 2013, 55(-), E341-E344.
  141. GULLESTAD, L. a et al. Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure. Circulation [online]. 2001, 103(2), 220-225 [cit. 2017-02-27].
  142. DENNERT, R. a et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antiviral Therapy [online]. 2010, 15(-), 193-201 [cit. 2017-02-27].
  143. BHATT, G.C. a et al. Use of Intravenous Immunoglobulin Compared With Standard Therapy is Associated With Improved Clinical Outcomes in Children With Acute Encephalitis Syndrome Complicated by Myocarditis. Pediatr Cardiol. 2012, 33(-), 1370-1376.
  144. DRUCKER, N.A. a et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation [online]. 1994, 89(1), 252-257 [cit. 2017-02-27].
  145. MCNAMARA, D.M. a et al. Intravenous Immune Globulin in the Therapy of Myocarditis and Acute Cardiomyopathy. Circulation [online]. 1997, 95(11), 2476-2478 [cit. 2017-02-28].
  146. MCNAMARA, D.M. a et al. Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. Circulation [online]. [cit. 2017-02-28].
  147. GOLAND, S. a et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: Series of six patients and review of liter Can J Cardiol. [online]. 2008, 24(7), 571-574 [cit. 2017-02-28].
  148. YU, D.Q. a et al. Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: A retrospective study. Exp Ther Med. [online]. 2014, 7(1), 97-102 [cit. 2017-02-28].
  149. Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders. Circulation [online]. 2003, 107(6), 857-863 [cit. 2017-02-28].
  150. WOJNICZ, R. a et al. Randomized, Placebo-Controlled Study for Immunosuppressive Treatment of Inflammatory Dilated Cardiomyopathy. Circulation [online]. 2001, 104(1), 39-45 [cit. 2017-02-28].
  151. FRUSTACI, A. a et al. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. European Heart Journal [online]. 2009, 30(16), 1995-2002 [cit. 2017-02-28].
  152. Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy. Clinical Trials [online]. -: -, 2007 [cit. 2017-02-28].
  153. DOESCH, A.O. a et al. Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy: Abstract. Journal of Clinical Apheresis [online]. 2009, 24(4), 141-149 [cit. 2017-02-28].
  154. KÜHL, U. a et al. Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction. Circulation [online]. 2003, 107(22), 2793- [cit. 2017-02-28].
  155. SCHULTHEISS, H.P. a et al. Late-Breaking Clinical Trial Abstracts From the American Heart Association’s Scientific Sessions 2008: The Effect of Subcutaneous Treatment with Interferon-Beta-1b Over 24 Weeks on Safety, Virus Elimination and Clinical Outcome in Patients with Chronic Viral Cardiomyopathy. 2008, 118(22), 2310-2317.
  156. SCHMIDT-LUCKE, C. a et al. Interferon Beta Modulates Endothelial Damage in Patients with Cardiac Persistence of Human Parvovirus B19 Infection. The Journal of Infectious Diseases [online]. 2010, 201(6), 936-945 [cit. 2017-02-28].
  157. AARON, K.D., PAGANI F.D. Chapter 29: Mechanical Circulatory Support. In.: D.P., ZIPES, MANN D.L., LIBBY P., BONOW R.O. a BRAUNWALD E. (eds.). Braunwald´s Heart Disease: A Textbook of Cardiovascular medicine. Tenth edition. Philadelphia: Elsevier Saunders, 2015. pp. 590-599. ISBN 978-1-4557-5133-4.
  158. RAJAGOPAL, S. a et al. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: A review of the Extracorporeal Life Support Organization registry. Crit Care Med. 2010, 38(2), 328-327.
  159. HSU, K.H. a et al. Extracorporeal membranous oxygenation support for acute Fulminant myocarditis: analysis of a single center’s experience. European Journal of Cardio-thoracic Surgery. 2011, 40(-), 682-688.
  160. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support.: Abstract. Critical Care Medicine [online]. 2011, 39(5), 1029-1035 [cit. 2017-02-28].
  161. YOSHIZAWA, S. a et al. Outcome of Patients Having Heart Transplantation for Lymphocytic Myocarditis. The American Journal of Cardiology. 2013, 112(-), 405-410.
  162. MOLONEY, E.D. a et al. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant. [online]. 2005, 24(8), 1103-1110 [cit. 2017-02-28].
  163. Indikace k ortotopické transplantaci srdce. PIRK, J., I. MÁLEK a et al. Transplantace srdce. Praha: Nakladatelství Karolinum, 2008, s. 72-74. ISBN 978-80-246-1606-3.
  164. KINDERMANN, I. a et al. Predictors of Outcome in Patients With Suspected Myocarditis. Circulation [online]. 2008, 118(6), 639-648 [cit. 2017-02-28].
  165. BLAUWET, L. a et al. Progress in Cardiovascular Diseases. 2010, 52(-), 274-288.
  166. BANKA, P. a et al. Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study. Journal of Cardiovascular Magnetic Resonance. 2015, 17(-), 1-8.
  167. MAVROGENI, S. a et al. Myocarditis as a precipitating factor for heart failure: evaluation and 1-year follow-up using cardiovascular magnetic resonance and endomyocardial biopsy. European Journal of Heart Failure. 2011, 13(-), 830-837.
  168. ANSARI, A. a et al. Drug-Induced Toxic Myocarditis. Tex Heart Inst J. [online]. 2003, 30(1), 76-79 [cit. 2017-02-28].
  169. AGEWALL, S. a et al. Troponin elevation in coronary vs. non-coronary disease. European Heart Journal [online]. 2011, 32(4), 404-411 [cit. 2017-02-28].
  170. SCHULTZ, J.C. a et al. Diagnosis and Treatment of Viral Myocarditis. Mayo Clin Proc [online]. 2009, 84(11), 1001-1009 [cit. 2017-03-01].

Author of the opening picture: Raúl Ruano Ruiz

Written by

  • Abbreviations

    ENGLISH TRANSLATION UNDER CONSTRUCTION

    18-F FDG            izotop fluoru – fluorodeoxyglukóza

    2CH                     2 komorový

    3D IT T1             název sekvence pro průkaz LGE

    4CH                     4 komorový

    ACE-I               …

  • Discussion

    The examined group consisted mostly of young males up to the age of 40. Majority of patients (77 %) had increased troponin I level and generally, the examined group showed a strong heterogeneity in the question of symptoms and examinations´ findings….

  • Results

    Clinical characteristics

    Clinical characteristics of the examined group are presented in Table 6. Patients were of the average age of 35 ± 14 years with considerable predominance of males (24 males and 6 females). The only statistically sig…